C25
Conditions
Interventions
Group 1: Patients with ductal adenocarcinoma of the pancreas without perioperaitve aspirin intake
Group 2: Patients with ductal adenocarcinoma of the pancreas with perioperaitve aspirin intake (100mg/
Sponsors
Klinikum der Universität München AVT Chirurgie
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients undergoing pancreatic surgery at our institution between 01/2014 and 11/2016 . Inclusion criteria were: (1) confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC) by pathology, (2) exclusion of distant metastasis at time of surgery, (3) successful resection of primary tumor with curative intent, (4) postoperative survival and/or follow-up of at least 12 weeks, (5) disease-free survival of at least 6 weeks. Since we wanted to focus our analysis on the metastases that might be favored by the perioperative period, we excluded patients who developed metastases within the first 6 weeks after resection, as these must have presumably already existed at the time of surgery.
Exclusion criteria
Exclusion criteria: Patients with diagnosis other than PDAC were excluded as well as patients that suffered from locally advanced disease that underwent neoadjuvant therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study is a monocentric retropective cohort study. All patients with ductal adenocarcinoma of the pancreas will be included that have been operated between 01/2014 und 11/2016 at Klinikum Großhadern. Patients with perioperative aspirin intake and patients without aspirin intake shall be compared. The following variables were extracted from the database as possible confounders: age, sex, American society of anesthesiologist (ASA) score, body mass index (BMI), preoperative serum level of carboanhydrate antigen 19-9 (CA19-9), preoperative platelet count, type of resection, intraoperative blood transfusions received, necessity for vascular resection, TNM stage, maximum tumor diameter, examined lymph nodes, lymph node ratio (number of positive nodes divided by resected nodes), residual tumor status (R0 wide, R0 narrow, R1; according to (18)), tumor grading, perineural, vascular, and lymphovascular invasion, and administration of adjuvant therapy. We aim to perform a propensity score matching and compare patients with log-rank test and cox regression analysis. | — |
Countries
Germany
Contacts
Public ContactElise Pretzsch
Klinikum der Universität München AVT Chirurgie
Outcome results
None listed